Intra-Cellular Therapies, Inc.ITCI
Market cap
$13.4B
P/E ratio
| 2013/03 | 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Stock-based compensation | - | 391,393 | 4 | 11 | 15 | 15 | 17 | 21 | 24 | 34 | 43 | 53 | 64 |
| Cash from operations | -5,930 | -22,591,265 | -22,807,150 | -102,279,965 | -91,257,227 | -80,491,812 | -118,169,113 | -127,983,241 | -230,072,845 | -259,543,485 | -270 | -124 | -73 |
| Capital expenditures | - | -33,255 | -11,762 | -860,595 | -48,964 | -723,429 | -391,268 | -700,395 | -266,724 | -325,738 | -1 | -0 | -0 |
| Cash from investing | - | 1 | -66,734,290 | -361,779,396 | 92 | -92,717,715 | 135 | 177 | -480,295,000 | 280 | -128 | 106 | -335 |
| Cash from financing | 10,000 | 41 | 116 | 450 | 477,734 | 162 | 685,188 | 3 | 664 | 12 | 455 | 18 | 568 |
| Free cash flow | - | ||||||||||||
| FCF margin (%) | - | - |